Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials

The National Institutes of Health (NIH), through its National Institute on Aging (NIA), has forecasted a funding opportunity titled “Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials,” under opportunity number FOR-RFA-AG-26-019. The purpose of this opportunity is to support the development and implementation of multi-site Phase Ib through Phase III clinical trials that focus on pharmacological and non-pharmacological interventions aimed at preventing, delaying, or treating symptoms associated with Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD). The trials must utilize the infrastructure provided by the Alzheimer’s Clinical Trials Consortium (ACTC), a collaborative network that includes applicants, the NIA, and the ACTC leadership. The ACTC infrastructure offers trial coordination and management resources essential for rigorous and scalable clinical trial implementation. This initiative focuses on addressing the full spectrum of AD/ADRD, from pre-symptomatic stages to more severe conditions. By leveraging the ACTC framework, selected investigators will benefit from expert guidance and support in trial design, implementation, and oversight. The NOFO (Notice of Funding Opportunity) will utilize the R01 activity code, which is commonly used for health-related research and development projects requiring substantial project management and experimental complexity. This opportunity is categorized under “Health” in terms of funding activity and is part of Assistance Listing 93.866, which pertains to Aging Research. While the funding details, including total funding available, award ceiling, and award floor, have not yet been disclosed, this forecast enables applicants to begin early planning and establish collaborative partnerships that align with the NIH’s strategic goals for aging and dementia research. The estimated number of awards is not specified at this time. Eligible applicants include a broad spectrum of organizations such as public and state-controlled institutions of higher education, independent school districts, state and county governments, federally recognized Native American tribal governments, small businesses, public housing authorities, for-profit organizations, nonprofits with 501(c)(3) status (excluding institutions of higher education), tribal organizations other than federally recognized governments, and private institutions of higher education. This wide eligibility base is designed to foster broad participation and innovative approaches to solving the complex challenges posed by AD/ADRD. As this is a forecasted opportunity, applications are not yet being accepted. The estimated date for posting the full funding announcement is August 1, 2025. The estimated application due date is October 5, 2025, with awards expected to be made by July 1, 2026. Funded projects are anticipated to begin on July 1, 2026. The forecasted status provides a valuable window for potential applicants to prepare comprehensive, competitive applications and to coordinate with ACTC and NIA leadership. For further information, prospective applicants are encouraged to contact Laurie Ryan, Ph.D., at the National Institute on Aging. She can be reached by phone at 301-496-9350 or via email at ryanl@mail.nih.gov. Interested parties should monitor Grants.gov and the NIH website for updates regarding the official NOFO release and application instructions.